Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

NSE/GLAXO stock hub

NSE/GLAXO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/GLAXOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

420.9B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/GLAXO

In the news

Latest news · NSE/GLAXO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E37.5

P25 24.9P50 32.4P75 45.7

Trailing P/E41.2

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC44.7

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/GLAXO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

198

Groups with data

Currency

INR

Showing 198 of 198 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	3,113
Employees Change	-98%
Employees Change Percent	-3.05
Enterprise value	INR 400.7B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - General
Isin	INE159A01016
Last refreshed	2026-05-10
Market cap	INR 420.9B
Price	INR 2,480
Price currency	INR
Rev Per Employee	12,209,252.81x
Sector	Healthcare
Sic	2834
Symbol	nse/GLAXO
Website	https://india-pharma.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.43%
EV Earnings	39.24x
EV/EBIT	32.65x
EV/EBITDA	31.27x
EV/Sales	10.54x
Forward P/E	37.47x
P/B ratio	24.65x
P/E ratio	41.23x
P/S ratio	11.07x
PE Ratio10 Y	61.24x
PE Ratio3 Y	51.43x
PE Ratio5 Y	46.25x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	32.29%
EBITDA Margin	33.24%
Gross margin	63.64%
Gross Profit	INR 24.2B
Gross Profit Growth	6.18%
Gross Profit Growth Q	14.77%
Gross Profit Growth3 Y	7.25%
Gross Profit Growth5 Y	5.08%
Net Income	INR 10.2B
Net Income Growth	18.83%
Net Income Growth Q	28.6%
Net Income Growth Quarters	8%
Net Income Growth Years	1%
Net Income Growth3 Y	-15.57%
Net Income Growth5 Y	16.2%
Pretax Margin	36.61%
Profit Margin	26.86%
Profit Per Employee	INR 3.3M
Profitable Years	21
Roa5y	13.37
Roe5y	29.34
ROIC	44.71

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	5.54%
Cagr15y	7.36%
Cagr1y	-11.86%
Cagr20y	8.71%
Cagr3y	27.9%
Cagr5y	14.06%
Div CAGR10	8.01%
Div CAGR3	19.06%
Div CAGR5	12.47%
EPS Growth	18.84
EPS Growth Q	28.59
EPS Growth Quarters	8
EPS Growth Years	1
EPS Growth3 Y	-15.57
EPS Growth5 Y	16.21
Revenue Growth	2.59x
Revenue Growth Q	9.67x
Revenue Growth Quarters	1x
Revenue Growth Years	2x
Revenue Growth3 Y	5.1x
Revenue Growth5 Y	3.76x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 20.6B
Debt	INR 357.1M
Debt EBITDA	INR 0.03
Debt Equity	INR 0.02
Equity	INR 17.1B
Interest Coverage	453.9
Net Cash	INR 20.3B
Net Cash By Market Cap	INR 4.81
Net Cash Growth	-3.38%
Net Debt EBITDA	INR -1.6
Net Debt Equity	INR -1.19
Tangible Book Value	INR 17B
Tangible Book Value Per Share	INR 100
WACC	4.77

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0%
Dividend Growth	-15.63%
Dividend Growth Years	0%
Dividend per share	INR 42
Dividend Years	25
Dividend Yield	1.7%
Ex Div Date	2025-05-30
Last Dividend	INR 42

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	71.42%
1Y total return	-11.85%
200-day SMA	2,597.4
3Y total return	109.26%
50-day SMA	2,433.7
50-day SMA vs 200-day SMA	50under200
5Y total return	93.03%
All Time High	3,515.7
All Time High Change	-29.45%
All Time High Date	2025-06-05
All Time Low	110
All Time Low Change	2,154.91%
All Time Low Date	2001-09-27
ATR	66.69
Beta	0.1
Ch YTD	0.27
High	2,504.9
High52	3,515.7
High52 Date	2025-06-05
High52ch	-29.45%
Low	2,441
Low52	2,217.6
Low52 Date	2026-03-30
Low52ch	11.85%
Ma50ch	1.92%
Price vs 200-day SMA	-4.5%
RSI	58.22
RSI Monthly	50.46
RSI Weekly	47.8
Sharpe ratio	-0.44x
Sortino ratio	-0.45
Total Return	1.71%
Tr YTD	0.27
Tr15y	190.02%
Tr1m	6.3%
Tr1w	5.55%
Tr3m	-0.14%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 12.3B
Operating Income Growth	19.01
Operating Income Growth Q	28.52
Operating Income Growth3 Y	17.79
Operating Income Growth5 Y	14.38
Operating margin	32.29

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,252,122%
Shares Insiders	0%
Shares Institutions	9.81%
Shares Qo Q	0%
Shares Yo Y	-0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	72,880.75x
Bv Per Share	100.8
Ch10y	38.48
Ch15y	116.2
Ch1m	6.3
Ch1w	5.55
Ch1y	-12.98
Ch20y	246.7
Ch3m	-0.14
Ch3y	98.57
Ch5y	69.24
Ch6m	-4.15
Change	-0.04%
Change From Open	-0.04
Close	2,481.3
Days Gap	0
Depreciation Amortization	359,733,250
Dollar Volume	168,766,416
Earnings Date	2026-05-13
EBIT	INR 12.3B
EBITDA	INR 12.6B
EPS	INR 60.26
F Score	2
Fiscal Year End	March
Founded	1,924
Graham Number	369.08577
Graham Upside	-85.12
Income Tax	INR 3.7B
Is Primary Listing	0
Last Earnings Date	2026-02-09
Last Report Date	2025-12-31
Last Split Date	2018-09-11
Last Split Type	Forward
Lynch Fair Value	INR 975
Lynch Upside	-60.7
Ma150	2,508.9
Ma150ch	-1.14%
Ma20	2,419.2
Ma20ch	2.53%
Next Earnings Date	2026-05-13
Open	2,481.3
Payment Date	2025-07-27
Position In Range	61.66
Price Date	2026-05-08
Price EBITDA	INR 33.32
Ptbv Ratio	24.77
Relative Volume	0.97x
Revenue	38,007,404,000x
Tax By Revenue	9.75x
Tax Rate	26.63%
Tr20y	430.95%
Tr6m	-4.15%
Volume	68,040

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/GLAXO dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.7%

$42.0 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+12.5%

0 consecutive years of growth

Total shareholder yield

+1.7%

Next ex-dividend date: 2025-05-30

Performance

NSE/GLAXO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/GLAXO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+9.8%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.0%

Negative means the company is buying back shares.

Technical

NSE/GLAXO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

58.2

Neutral momentum band

Price vs 200-day MA

-4.5%

50/200-day relationship not available

Beta (5Y)

0.10

Less volatile than the market

Sharpe ratio

-0.44

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/GLAXO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/GLAXO stock rating?

nse/GLAXO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/GLAXO analysis?

The full report lives at /stocks/nse/GLAXO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/GLAXO?

The latest report frames nse/GLAXO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/GLAXO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.